UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended April 1, 2018
OR
TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
COMMISSION FILE NUMBER 1-3619
----
PFIZER INC.
(Exact name of registrant as specified in its charter)
DELAWARE
(State of Incorporation)
13-5315170
(I.R.S. Employer Identification No.)
235 East 42nd Street, New York, New York 10017
(Address of principal executive offices) (zip code)
(212) 733-2323
(Registrant s telephone number)
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
YES X
NO ___
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
YES X
NO ___
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act (check one):
Large Accelerated filer X Accelerated filer ___ Non-accelerated filer ___ Smaller reporting company ___ Emerging growth company ___
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ___
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YES ____
NO X
At May 7, 2018, 5,849,571,048 shares of the issuer s voting common stock were outstanding.
Table of Contents
PART I. FINANCIAL INFORMATION
Page
Item 1.
Financial Statements
Condensed Consolidated Statements of Income for the three months ended April 1, 2018 and April 2, 2017
Condensed Consolidated Statements of Comprehensive Income for the three months ended April 1, 2018 and April 2, 2017
Condensed Consolidated Balance Sheets as of April 1, 2018 and December 31, 2017
Condensed Consolidated Statements of Cash Flows for the three months ended April 1, 2018 and April 2, 2017
Notes to Condensed Consolidated Financial Statements
10
Review Report of Independent Registered Public Accounting Firm
49
Item 2.
Management s Discussion and Analysis of Financial Condition and Results of Operations
50
Item 3.
Quantitative and Qualitative Disclosures About Market Risk
105
Item 4.
Controls and Procedures
105
PART II. OTHER INFORMATION
Item 1.
Legal Proceedings
106
Item 1A.
Risk Factors
106
Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
107
Item 3.
Defaults Upon Senior Securities
107
Item 4.
Mine Safety Disclosures
107
Item 5.
Other Information
107
Item 6.
Exhibits
108
Signature
109
GLOSSARY OF DEFINED TERMS
Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Quarterly Report on Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this Quarterly Report on Form 10-Q, most of which are explained or defined below:
2017 Financial Report
Financial Report for the fiscal year ended December 31, 2017, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2017
2017 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2017
ACA (Also referred to as U.S. Healthcare Legislation)
U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act
ACIP
Advisory Committee on Immunization Practices
ALK
anaplastic lymphoma kinase
Alliance revenues
Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
Anacor
Anacor Pharmaceuticals, Inc.
AOCI
Accumulated Other Comprehensive Income
Astellas
Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ASU
Accounting Standards Update
ATM-AVI
aztreonam-avibactam
Avillion
Avillion LLP
BMS
Bristol-Myers Squibb Company
BRCA
BReast CAncer susceptibility gene
CDC
U.S. Centers for Disease Control and Prevention
Citibank
Citibank N.A.
CML
chronic myelogenous leukemia
Developed Markets
U.S., Western Europe, Japan, Canada, Australia, South Korea, Scandinavian countries, Finland and New Zealand
EEA
European Economic Area
EH
Essential Health
EMA
European Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey
EPS
earnings per share
EU
European Union
Exchange Act
Securities Exchange Act of 1934, as amended
FASB
Financial Accounting Standards Board
FDA
U.S. Food and Drug Administration
GAAP
Generally Accepted Accounting Principles
GIST
gastrointestinal stromal tumors
GPD
Global Product Development
HER2-
human epidermal growth factor receptor 2-negative
hGH-CTP
human growth hormone
HIS
Hospira Infusion Systems
Hisun Pfizer
Hisun Pfizer Pharmaceuticals Company Limited
Hospira
Hospira, Inc.
HR+
hormone receptor-positive
ICU Medical
ICU Medical, Inc.
IH
Innovative Health
IPR&D
in-process research and development
IRS
U.S. Internal Revenue Service
IV
intravenous
Janssen
Janssen Biotech Inc.
J&J
Johnson & Johnson Corp.
King
King Pharmaceuticals, Inc.
LDL
low density lipoprotein
LEP
Legacy Established Products
LIBOR
London Interbank Offered Rate
Lilly
Eli Lilly & Company
LOE
loss of exclusivity
MCC
Merkel Cell Carcinoma
MCO
Managed Care Organization
MD&A
Management s Discussion and Analysis of Financial Condition and Results of Operations
Medivation
Medivation, Inc.
Merck
Merck & Co., Inc.
Meridian
Meridian Medical Technologies, Inc.
Moody s
Moody s Investors Service
NDA
new drug application
NovaQuest
NovaQuest Co-Investment Fund V, L.P.
NSCLC
non-small cell lung cancer
NYSE
New York Stock Exchange
OPKO
OPKO Health, Inc.
OTC
over-the-counter
PARP
poly ADP ribose polymerase
PBM
Pharmacy Benefit Manager
Pharmacia
Pharmacia Corporation
PP&E
Property, plant & equipment
Quarterly Report on Form 10-Q
Quarterly Report on Form 10-Q for the quarterly period ended April 1, 2018
RCC
renal cell carcinoma
R&D
research and development
RPI
RPI Finance Trust
Sandoz
Sandoz, Inc., a division of Novartis AG
SEC
U.S. Securities and Exchange Commission
SFJ
SFJ Pharmaceuticals Group
Shire
Shire International GmbH
SIP
Sterile Injectable Pharmaceuticals
S&P
Standard and Poor s
StratCO
Strategy and Commercial Operations
Tax Cuts and Jobs Act or TCJA
H.R.1, An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018
U.K.
United Kingdom
U.S.
United States
VAI
Voluntary Action Indicated
ViiV
ViiV Healthcare Limited
WRD
Worldwide Research and Development
PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS, EXCEPT PER COMMON SHARE DATA)
April 1,
2018
April 2,
2017
Revenues
12,906
12,779
Costs and expenses:
Cost of sales(a)
2,563
2,468
Selling, informational and administrative expenses(a)
3,412
3,315
Research and development expenses(a)
1,743
1,716
Amortization of intangible assets
1,196
1,186
Restructuring charges and certain acquisition-related costs
43
84
Other (income)/deductions net
(178
60
Income from continuing operations before provision for taxes on income
4,127
3,951
Provision for taxes on income
556
821
Income from continuing operations
3,571
3,130
Discontinued operations net of tax
(1
Net income before allocation to noncontrolling interests
3,570
3,130
Less: Net income attributable to noncontrolling interests
Net income attributable to Pfizer Inc.
3,561
3,121
Earnings per common share basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.60
0.52
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.60
0.52
Earnings per common share diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders
0.59
0.51
Discontinued operations net of tax
Net income attributable to Pfizer Inc. common shareholders
0.59
0.51
Weighted-average shares basic
5,957
6,006
Weighted-average shares diluted
6,057
6,092
Cash dividends paid per common share
0.34
0.32
(a)
Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
April 1,
2018
April 2,
2017
Net income before allocation to noncontrolling interests
3,570
3,130
Foreign currency translation adjustments, net
758
228
Reclassification adjustments
15
773
228
Unrealized holding losses on derivative financial instruments, net
(114
(9
Reclassification adjustments for (gains)/losses included in net income(a)
44
(241
(69
(251
Unrealized holding gains on available-for-sale securities, net
160
150
Reclassification adjustments for (gains)/losses included in net income(a)
(174
137
Reclassification adjustments for unrealized gains included in Retained earnings(b)
(462
(476
287
Benefit plans: actuarial gains, net
163
Reclassification adjustments related to amortization
62
163
Reclassification adjustments related to settlements, net
37
52
Other
(86
45
175
261
Benefit plans: prior service (costs)/credits and other, net
Reclassification adjustments related to amortization
(46
(45
Reclassification adjustments related to curtailments, net
(7
(7
Other
(51
(52
Other comprehensive income, before tax
352
474
Tax provision on other comprehensive (loss)/income
432
25
Other comprehensive (loss)/income before allocation to noncontrolling interests
(80
449
Comprehensive income before allocation to noncontrolling interests
3,490
3,579
Less: Comprehensive income attributable to noncontrolling interests
10
15
Comprehensive income attributable to Pfizer Inc.
3,480
3,563
(a)
Reclassified into Other (income)/deductions net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see Note 7F. Financial Instruments: Derivative Financial Instruments and Hedging Activities.
(b)
For additional information, see Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS OF DOLLARS)
April 1,
2018
December 31,
2017
(Unaudited)
Assets
Cash and cash equivalents
2,302
1,342
Short-term investments
9,119
18,650
Trade accounts receivable, less allowance for doubtful accounts: 2018 $597; 2017 $584
9,452
8,221
Inventories
8,148
7,578
Current tax assets
3,624
3,050
Other current assets
2,126
2,289
Assets held for sale
64
12
Total current assets
34,835
41,141
Long-term investments
6,945
7,015
Property, plant and equipment, less accumulated depreciation: 2018 $16,665; 2017 $16,172
13,971
13,865
Identifiable intangible assets, less accumulated amortization
47,690
48,741
Goodwill
56,393
55,952
Noncurrent deferred tax assets and other noncurrent tax assets
1,883
1,855
Other noncurrent assets
2,896
3,227
Total assets
164,612
171,797
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2018 $4,763; 2017 $3,546
9,010
9,953
Trade accounts payable
3,879
4,656
Dividends payable
2,029
Income taxes payable
1,614
477
Accrued compensation and related items
1,911
2,196
Other current liabilities
10,950
11,115
Total current liabilities
27,365
30,427
Long-term debt
31,831
33,538
Pension benefit obligations, net
5,171
5,926
Postretirement benefit obligations, net
1,488
1,504
Noncurrent deferred tax liabilities
5,967
3,900
Other taxes payable
16,605
18,697
Other noncurrent liabilities
5,644
6,149
Total liabilities
94,071
100,141
Commitments and Contingencies
Preferred stock
21
21
Common stock
465
464
Additional paid-in capital
84,599
84,278
Treasury stock
(95,460
(89,425
Retained earnings
89,961
85,291
Accumulated other comprehensive loss
(9,402
(9,321
Total Pfizer Inc. shareholders equity
70,184
71,308
Equity attributable to noncontrolling interests
358
348
Total equity
70,541
71,656
Total liabilities and equity
164,612
171,797
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Three Months Ended
(MILLIONS OF DOLLARS)
April 1,
2018
April 2,
2017
Operating Activities
Net income before allocation to noncontrolling interests
3,570
3,130
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization
1,567
1,555
Asset write-offs and impairments
35
Loss on sale of HIS net assets
37
TCJA impact(a)
(68
Deferred taxes from continuing operations
294
38
Share-based compensation expense
182
218
Benefit plan contributions in excess of expense
(692
(986
Other adjustments, net
(164
(225
Other changes in assets and liabilities, net of acquisitions and divestitures
(2,715
(2,217
Net cash provided by operating activities
1,983
1,584
Investing Activities
Purchases of property, plant and equipment
(386
(358
Purchases of short-term investments
(913
(701
Proceeds from redemptions/sales of short-term investments
6,463
2,232
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less
4,507
3,778
Purchases of long-term investments
(605
(740
Proceeds from redemptions/sales of long-term investments
576
844
Acquisitions of businesses, net of cash acquired
(585
Other investing activities, net
25
297
Net cash provided by investing activities
9,667
4,768
Financing Activities
Proceeds from short-term borrowings
428
2,554
Principal payments on short-term borrowings
(2,493
(2,519
Net payments on short-term borrowings with original maturities of three months or less
(83
(2,110
Proceeds from issuance of long-term debt
5,273
Principal payments on long-term debt
(355
(1,253
Purchases of common stock
(6,063
(5,000
Cash dividends paid
(2,032
(1,945
Proceeds from exercise of stock options
372
313
Other financing activities, net
(495
(220
Net cash used in financing activities
(10,720
(4,907
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
55
21
Net increase in cash and cash equivalents and restricted cash and cash equivalents
985
1,465
Cash and cash equivalents and restricted cash and cash equivalents, beginning
1,431
2,666
Cash and cash equivalents and restricted cash and cash equivalents, end
2,416
4,131
Supplemental Cash Flow Information
Non-cash transactions:
Receipt of ICU Medical common stock(b)
428
Promissory note from ICU Medical(b)
75
Cash paid during the period for:
Income taxes
257
195
Interest
259
216
Interest rate hedges
20
32
(a)
As a result of the enactment of the TCJA in December 2017, Pfizer s 2018 Provision for taxes on income was favorably impacted by approximately $68 million, primarily related to certain tax initiatives associated with the lower U.S. tax rate as a result of the TCJA.
(b)
In connection with the sale of the HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million, which was repaid in full as of December 31, 2017. For additional information, see Note 2B. Acquisition, Sale of Hospira Infusion Systems Net Assets, Licensing Arrangement and Collaborative Arrangements: Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH).
- continued -
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the condensed consolidated balance sheet that sum to the total of the same amounts shown in the condensed consolidated statement of cash flows:
(MILLIONS OF DOLLARS)
April 1, 2018
December 31,
2017
Cash and cash equivalents
2,302
1,342
Restricted cash and cash equivalents in Short-term investments
41
Restricted cash and cash equivalents in Long-term investments
73
Restricted cash and cash equivalents in Other current assets
14
Restricted cash and cash equivalents in Other noncurrent assets
75
Total cash and cash equivalents and restricted cash and cash equivalents shown in the condensed consolidated balance sheets
2,416
1,431
Amounts included in restricted cash represent those required to be set aside by a contractual agreement in connection with ongoing litigation or to secure delivery of Pfizer medicines at the agreed upon terms. The restriction will lapse upon the resolution of the litigation or the proper delivery of the medicines.
Amounts may not add due to rounding.
See Notes to Condensed Consolidated Financial Statements.
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q.
We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted.
The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three months ended February 25, 2018 and February 26, 2017. The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three months ended April 1, 2018 and April 2, 2017.
Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2017 Form 10-K.
We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements Note 18. Segment, Geographic and Other Revenue Information in Pfizer s 2017 Financial Report.
Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.
In the first quarter of 2018, as of January 1, 2018, we adopted eleven new accounting standards. See Note 1B for further information.
Our recent significant business development activities include:
On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH s operating results through February 2, 2017 and, therefore, our financial results, and EH s operating results, for the first quarter of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH s operating results, for the first quarter of 2018 do not reflect any contribution from HIS global operations.
On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH s operating results, and cash flows for the first quarter of 2017 reflect approximately two months of the small molecule anti-infectives business acquired from AstraZeneca and our financial results, EH s operating results, and cash flows for the first quarter of 2018 reflect three months of the small molecule anti-infective business acquired from AstraZeneca.
For additional information, see Note 2 and Notes to Consolidated Financial Statements Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Research and Development and Collaborative Arrangements, Equity-Method Investments and Cost-Method Investment in Pfizer s 2017 Financial Report.
B. Adoption of New Accounting Standards
On January 1, 2018, we adopted eleven new accounting standards. The quantitative impacts on our prior period condensed consolidated financial statements of adopting the following new standards are summarized in the tables within the section titled Impacts to our Condensed Consolidated Financial Statements, further below.
10
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Revenues We adopted a new accounting standard for revenue recognition and changed our revenue recognition policies accordingly. Generally, the previous revenue recognition standards permitted recognition when persuasive evidence of a contract existed, delivery had occurred, and the seller's price to the buyer was fixed or determinable. Under the new standard, revenue is recognized upon transfer of control of the product to our customer in an amount that reflects the consideration we expect to receive in exchange. We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $584 million on a pre-tax basis ($450 million after-tax). This amount includes $500 million (pre-tax) related to the timing of recognizing Other (income)/deductions net primarily for upfront and milestone payments on our collaboration arrangements ($394 million, pre-tax) and, to a lesser extent, product rights and out-licensing arrangements, and $84 million (pre-tax) related to the timing of recognizing Revenues and Cost of sales on product shipments. The impact of adoption did not have a material impact to our condensed consolidated statement of income for the three months ended April 1, 2018 or our condensed consolidated balance sheet as of April 1, 2018. For additional information, see Note 1C.
Financial Assets and Liabilities The new accounting standard related to the recognition and measurement of financial assets and liabilities makes the following changes to prior guidance and requires:
certain equity investments to be measured at fair value with changes in fair value now recognized in net income. However, equity investments that do not have readily determinable fair values may be measured at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer;
a qualitative assessment of equity investments without readily determinable fair values to identify impairment; and
separate presentation of financial assets and financial liabilities by measurement category and form of financial asset on the balance sheet or in the accompanying notes to the financial statements.
We adopted the new accounting standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $462 million on a pre-tax basis ($419 million after-tax) related to the net impact of unrealized gains and losses primarily on available-for-sale equity securities, restricted stock and private equity securities. In the first quarter of 2018, we recorded net unrealized gains on equity securities of $111 million. For additional information, see Note 4 and Note 7.
Presentation of Net Periodic Pension and Postretirement Benefit Cost We adopted a new accounting standard that requires the net periodic pension and postretirement benefit costs other than the service costs be presented in Other (income)/deductions net, and that the presentation be applied retrospectively. We adopted the presentation of the net periodic benefit costs other than service costs by reclassifying these costs from Cost of sales, Selling, informational and administrative expenses, Research and development expenses and Restructuring charges and certain acquisition-related costs to Other (income)/deductions net. We elected to apply the practical expedient as it is impracticable to determine the disaggregation of the cost components for amounts capitalized within Inventories and property, plant and equipment and amortized in each of those periods. We have therefore reclassified the prior period net periodic benefit costs/(credits) disclosed in Note 10 to apply the retrospective presentation for comparative periods.
As of January 1, 2018, only service costs will be included in amounts capitalized in Inventories or property, plant and equipment, while the other components of net periodic benefit costs will be included in Other (income)/deductions net. For additional information, see Note 4 and Note 10.
Income Tax Accounting The new guidance removes the prohibition against recognizing current and deferred income taxes for an intra-entity asset transfer until the asset has been sold to a third party, unless the asset transferred is inventory. We adopted the standard utilizing the modified retrospective method, and, therefore, no adjustments were made to amounts in our prior period financial statements. We recorded the cumulative effect of adopting the standard as an adjustment to decrease the opening balance of Retained earnings by $189 million.
Accounting for Hedging Activities The standard makes the following changes:
Permits hedge accounting for risk components in hedging relationships involving nonfinancial risk and interest rate risk;
Changes the guidance for designating fair value hedges of interest rate risk and for measuring the change in fair value of the hedged item in fair value hedges of interest rate risk;
No longer requires the separate measurement and reporting of hedge ineffectiveness, but requires the income statement presentation of the earnings effect of the hedging instrument with the earnings effect of the hedged item;
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Permits us to exclude the portion of the change in fair value of a currency swap that is attributable to a cross-currency basis spread from the assessment of hedge effectiveness; and
Simplifies hedge effectiveness testing.
We early adopted the new accounting standard on January 1, 2018 on a prospective basis. In the first quarter of 2018, we recorded income of $29 million in Other (income)/deductions net, whereas this item would have been classified in interest income in prior periods. For additional information, see Note 7F.
Reclassification of Certain Tax Effects from AOCI We early adopted a new accounting standard that provides guidance on the reclassification of certain tax effects from AOCI. Under the new guidance, we elected to reclassify the stranded tax amounts related to the TCJA from AOCI to Retained earnings. We adopted the new accounting standard utilizing the modified retrospective method, and recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of Retained earnings by $495 million, primarily due to the effect of the change in the U.S. Federal corporate tax rate. The impact on other stranded tax amounts related to the application of the TCJA was not material to our condensed consolidated financial statements.
Classification of Certain Transactions in the Statement of Cash Flows We retrospectively adopted an accounting standard that changed the presentation of certain information in the condensed consolidated statements of cash flows, including the classification of:
debt prepayment and extinguishment costs, resulting in an increase in Operating activities Other adjustments, net and a decrease in Financing activities Other financing activities, net of $5 million for the three months ended April 1, 2018; and
accreted interest on the settlement of commercial paper debt instruments, resulting in a decrease in Operating activities Other adjustments, net, and an increase in Financing activities Other financing activities, net of $24 million for the three months ended April 1, 2018.
The new standard also establishes guidance on the classification of certain cash flows related to contingent consideration in a business acquisition. Cash payments made soon after a business acquisition date will be classified as Investing activities, while payments made thereafter will be classified as Financing activities. Payments made in excess of the amount of the original contingent consideration liability will be classified as Operating activities. The adoption of this guidance will not have a material impact to our condensed consolidated financial statements.
Presentation of Restricted Cash in the Statement of Cash Flows We adopted, on a retrospective basis, the new accounting standard, which requires that Restricted cash and restricted cash equivalents be included with Cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown in the consolidated statements of cash flows. As a result, for the three months ended April 1, 2018, $25 million is presented as an increase in Cash, cash equivalents, restricted cash and restricted cash equivalents.
Definition of a Business We prospectively adopted the standard for determining whether business development transactions should be accounted for as acquisitions (or disposals) of assets or businesses. If substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, the transaction will not qualify for treatment as a business. To be considered a business, a set of integrated activities and assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create outputs, without regard as to whether a purchaser could replace missing elements. In addition, the definition of the term output has been narrowed to make it consistent with the updated revenue recognition guidance. In the first quarter of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard.
Derecognition of Nonfinancial Assets We prospectively adopted the standard, which applies to the full or partial sale or transfer of nonfinancial assets, including intangible assets, real estate and inventory. The standard provides that the gain or loss is determined by the difference between the consideration received and the carrying value of the asset. In the first quarter of 2018, there was no impact to our condensed consolidated financial statements from the adoption of this new standard.
Accounting for Modifications of Share-Based Payment Awards We prospectively adopted the standard, which clarifies that certain changes in the terms or conditions of a share-based payment award be accounted for as a modification. There was no impact to our condensed consolidated financial statements from the adoption of this new standard.
Impacts to our Condensed Consolidated Financial Statements The impacts on our prior period condensed consolidated financial statements of adopting the new standards described above are summarized in the following tables:
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Adoption of the standard related to pension and postretirement benefit costs impacted our prior period condensed consolidated statement of income as follows: